These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 7849490)

  • 1. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey.
    Galbraith WM; Hobson WC; Giclas PC; Schechter PJ; Agrawal S
    Antisense Res Dev; 1994; 4(3):201-6. PubMed ID: 7849490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide.
    Henry SP; Beattie G; Yeh G; Chappel A; Giclas P; Mortari A; Jagels MA; Kornbrust DJ; Levin AA
    Int Immunopharmacol; 2002 Nov; 2(12):1657-66. PubMed ID: 12469940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys.
    Webb MS; Tortora N; Cremese M; Kozlowska H; Blaquiere M; Devine DV; Kornbrust DJ
    Antisense Nucleic Acid Drug Dev; 2001 Jun; 11(3):155-63. PubMed ID: 11446591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after intravenous infusion to cynomolgus monkeys.
    Wallace TL; Bazemore SA; Kornbrust DJ; Cossum PA
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1306-12. PubMed ID: 8819516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action.
    Henry SP; Giclas PC; Leeds J; Pangburn M; Auletta C; Levin AA; Kornbrust DJ
    J Pharmacol Exp Ther; 1997 May; 281(2):810-6. PubMed ID: 9152389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of alternative complement pathway dysregulation by a phosphorothioate oligonucleotide in monkey and human serum.
    Henry SP; Jagels MA; Hugli TE; Manalili S; Geary RS; Giclas PC; Levin AA
    Nucleic Acid Ther; 2014 Oct; 24(5):326-35. PubMed ID: 25093529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In vitro anti-HIV activity of phosphorothioate alpha-anomeric oligodeoxynucleotides].
    Rayner B; Matsukura M; Morvan F; Cohen JS; Imbach JL
    C R Acad Sci III; 1989; 310(3):61-4. PubMed ID: 2516764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel enzymatic and immunological responses to oligonucleotides.
    Agrawal S; Rustagi PK; Shaw DR
    Toxicol Lett; 1995 Dec; 82-83():431-4. PubMed ID: 8597089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bolus intravenous injection of phosphorothioate oligonucleotides causes hypotension by acting as alpha(1)-adrenergic receptor antagonists.
    Iversen PL; Cornish KG; Iversen LJ; Mata JE; Bylund DB
    Toxicol Appl Pharmacol; 1999 Nov; 160(3):289-96. PubMed ID: 10544063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphorothioate oligonucleotides, suramin and heparin inhibit DNA-dependent protein kinase activity.
    Hosoi Y; Matsumoto Y; Tomita M; Enomoto A; Morita A; Sakai K; Umeda N; Zhao HJ; Nakagawa K; Ono T; Suzuki N
    Br J Cancer; 2002 Apr; 86(7):1143-9. PubMed ID: 11953863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of interleukin 1 beta gene expression using antisense phosphorothioate oligonucleotides.
    Manson J; Brown T; Duff G
    Lymphokine Res; 1990; 9(1):35-42. PubMed ID: 2182947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue.
    Iversen P
    Anticancer Drug Des; 1991 Dec; 6(6):531-8. PubMed ID: 1772568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology.
    Gao WY; Han FS; Storm C; Egan W; Cheng YC
    Mol Pharmacol; 1992 Feb; 41(2):223-9. PubMed ID: 1371582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of platelet heparitinase by phosphorothioate DNA oligonucleotides.
    Graham LD; Mitchell SM; Underwood PA
    Biochem Mol Biol Int; 1995 Oct; 37(2):239-46. PubMed ID: 8673006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequence dependence of C5-propynyl-dU,dC-phosphorothioate oligonucleotide inhibition of the human IGF-I receptor: mRNA, protein, and cell growth.
    Fogarty RD; McKean SC; White PJ; Atley LM; Werther GA; Wraight CJ
    Antisense Nucleic Acid Drug Dev; 2002 Dec; 12(6):369-77. PubMed ID: 12568311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide.
    Temsamani J; Roskey A; Chaix C; Agrawal S
    Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):159-65. PubMed ID: 9212906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: dependence on phosphorothioate modification and reversal by heparin.
    Hartmann G; Krug A; Waller-Fontaine K; Endres S
    Mol Med; 1996 Jul; 2(4):429-38. PubMed ID: 8827713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the extent of thiolation and introduction of phosphorothioate internucleotide linkages on the anti-HIV activity of Suligovir [(s4dU)35].
    Horváth A; Beck Z; Bardos TJ; Dunn JA; Aradi J
    Bioorg Med Chem Lett; 2006 Oct; 16(20):5321-3. PubMed ID: 16920358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice.
    Zhao Q; Temsamani J; Zhou RZ; Agrawal S
    Antisense Nucleic Acid Drug Dev; 1997 Oct; 7(5):495-502. PubMed ID: 9361908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion.
    Iversen PL; Mata J; Tracewell WG; Zon G
    Antisense Res Dev; 1994; 4(1):43-52. PubMed ID: 8061515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.